공시 • Feb 18
Otonomy, Inc. Announces Executive Changes On February 15, 2023, the board of directors of the Otonomy, Inc. appointed H. Michael Hogan, a representative of Armanino LLP (Armanino), a consultant to the Company, to the Board. In connection and simultaneously with Mr. Hogan’s appointment to the Board, the size of the Board was reduced to one and Jay Lichter, Ph.D., James B. Breitmeyer, M.D., Ph.D., Jill Broadfoot, Vickie Capps, Ciara Kennedy, Ph.D., Iain McGill, Theodore R. Schroeder and David A. Weber, Ph.D. resigned from the Board. The directors did not resign because of any disagreement with the Company relating to its operations, policies or practices. Mr. Hogan will serve as a director pursuant to the Company’s engagement of Armanino, but will not receive any compensation for his service as the Company’s sole director. Price Target Changed • Nov 16
Price target increased to US$9.00 Up from US$6.00, the current price target is provided by 1 analyst. New target price is 6,823% above last closing price of US$0.13. Stock is down 94% over the past year. The company is forecast to post a net loss per share of US$0.77 next year compared to a net loss per share of US$0.81 last year. Price Target Changed • Aug 02
Price target decreased to US$5.83 Down from US$6.63, the current price target is an average from 4 analysts. New target price is 2,240% above last closing price of US$0.25. Stock is down 85% over the past year. The company is forecast to post a net loss per share of US$0.72 next year compared to a net loss per share of US$0.81 last year. Reported Earnings • May 10
First quarter 2022 earnings released: US$0.20 loss per share (vs US$0.23 loss in 1Q 2021) First quarter 2022 results: US$0.20 loss per share. Net loss: US$13.6m (loss widened 11% from 1Q 2021). Over the next year, revenue is expected to shrink by 100% compared to a 6.9% growth forecast for the industry in the US. Price Target Changed • Apr 27
Price target increased to US$6.50 Up from US$5.90, the current price target is an average from 5 analysts. New target price is 191% above last closing price of US$2.23. Stock is down 9.7% over the past year. The company is forecast to post a net loss per share of US$0.77 next year compared to a net loss per share of US$0.81 last year. Price Target Changed • Apr 21
Price target increased to US$6.50 Up from US$5.90, the current price target is an average from 5 analysts. New target price is 190% above last closing price of US$2.24. Stock is down 2.6% over the past year. The company is forecast to post a net loss per share of US$0.77 next year compared to a net loss per share of US$0.81 last year. Reported Earnings • Mar 03
Full year 2021 earnings: EPS exceeds analyst expectations Full year 2021 results: US$0.81 loss per share (up from US$1.10 loss in FY 2020). Net loss: US$51.2m (loss widened 14% from FY 2020). Products in clinical trials Phase II: 2 Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 2.5%. Over the next year, revenue is expected to shrink by 100% compared to a 20% growth forecast for the pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Reported Earnings • Nov 12
Third quarter 2021 earnings released: US$0.19 loss per share (vs US$0.22 loss in 3Q 2020) Third quarter 2021 results: Net loss: US$12.9m (loss widened 19% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Major Estimate Revision • Aug 11
Consensus forecasts updated The consensus outlook for 2021 has been updated. 2021 revenue forecast fell from US$183.8k to US$158.3k. EPS estimate increased from -US$0.81 to -US$0.78 per share. Pharmaceuticals industry in the US expected to see average net income growth of 14% next year. Consensus price target of US$6.30 unchanged from last update. Share price fell 5.5% to US$1.56 over the past week. Reported Earnings • Aug 06
Second quarter 2021 earnings released: US$0.19 loss per share (vs US$0.37 loss in 2Q 2020) Second quarter 2021 results: Net loss: US$12.5m (loss widened 9.2% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings. Major Estimate Revision • May 18
Consensus revenue estimates increase to US$183.8k The consensus outlook for revenues in 2021 has improved. 2021 revenue forecast increased from US$118.8k to US$183.8k. Forecast losses expected to reduce from -US$0.87 to -US$0.81 per share. Pharmaceuticals industry in the US expected to see average net income growth of 13% next year. Consensus price target of US$6.30 unchanged from last update. Share price rose 15% to US$2.37 over the past week. Reported Earnings • May 13
First quarter 2021 earnings released: US$0.23 loss per share (vs US$0.38 loss in 1Q 2020) First quarter 2021 results: Net loss: US$12.2m (loss widened 3.8% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings. Major Estimate Revision • Apr 14
Consensus forecasts updated The consensus outlook for 2021 has been updated. 2021 losses forecast to reduce from -US$1.09 to -US$0.87 per share. Revenue forecast unchanged from US$118.8k at last update. Pharmaceuticals industry in the US expected to see average net income growth of 16% next year. Consensus price target up from US$5.91 to US$6.10. Share price fell 16% to US$2.17 over the past week. Is New 90 Day High Low • Feb 23
New 90-day low: US$3.00 The company is down 31% from its price of US$4.37 on 24 November 2020. The American market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$101 per share. Major Estimate Revision • Feb 18
Analysts lower revenue estimates to US$91.7k The 2021 consensus revenue estimate decreased from US$7.56m. Earnings per share (EPS) also decreased, with analysts lowering their estimates from -US$1.01 to -US$1.06 for the same period. The Pharmaceuticals industry in the US is expected to see an average net income growth of 14% next year. The consensus price target of US$10.80 was unchanged from the last update. Share price is up 5.2% to US$5.63 over the past week. Analyst Estimate Surprise Post Earnings • Feb 13
Revenue and earnings miss expectations Revenue missed analyst estimates by 48%. Earnings per share (EPS) also missed analyst estimates by 5.6%. Over the next year, revenue is forecast to grow 2,669%, compared to a 31% growth forecast for the Pharmaceuticals industry in the US. Reported Earnings • Feb 13
Full year 2020 earnings released: US$1.10 loss per share (vs US$1.45 loss in FY 2019) Full year 2020 results: Net loss: US$44.7m (flat on FY 2019). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Price Target Changed • Dec 19
Price target raised to US$10.80 Up from US$9.40, the current price target is an average from 5 analysts. The new target price is 69% above the current share price of US$6.38. As of last close, the stock is up 158% over the past year. Is New 90 Day High Low • Dec 18
New 90-day high: US$5.98 The company is up 51% from its price of US$3.95 on 18 September 2020. The American market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$149 per share. Is New 90 Day High Low • Dec 02
New 90-day high: US$4.79 The company is up 29% from its price of US$3.70 on 02 September 2020. The American market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$125 per share. Analyst Estimate Surprise Post Earnings • Nov 07
Revenue and earnings miss expectations Revenue missed analyst estimates by 9.1%. Earnings per share (EPS) also missed analyst estimates by 9.6%. Over the next year, revenue is forecast to grow 1,756%, compared to a 30% growth forecast for the Pharmaceuticals industry in the US. Reported Earnings • Nov 07
Third quarter 2020 earnings released: US$0.22 loss per share Third quarter 2020 results: Net loss: US$10.9m (loss widened 8.2% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Is New 90 Day High Low • Oct 03
New 90-day high: US$4.44 The company is up 41% from its price of US$3.16 on 02 July 2020. The American market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$117 per share.